9 Analysts Have This to Say About Crinetics Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Crinetics Pharmaceuticals (NASDAQ:CRNX) has received 9 bullish ratings from analysts in the last quarter, with an average 12-month price target of $39.0. The ratings have remained unchanged from the previous quarter.
August 31, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Crinetics Pharmaceuticals has received positive analyst ratings, indicating potential growth.
The company has received 9 bullish ratings from analysts in the last quarter, indicating a positive outlook for the stock. The average 12-month price target of $39.0 suggests potential upside for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100